Anti-N-methyl-D-aspartate receptor encephalitis presenting with acute psychosis in a preteenage girl: a case report
© Maggina et al.; licensee BioMed Central Ltd. 2012
Received: 13 November 2011
Accepted: 1 May 2012
Published: 30 July 2012
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a rare, newly defined autoimmune clinical entity that presents with atypical clinical manifestations. Most patients with anti-N-methyl-D-aspartate receptor encephalitis develop a progressive illness from psychosis into a state of unresponsiveness, with catatonic features often associated with abnormal movements and autonomic instability. This is the first report of anti-N-methyl-D-aspartate receptor encephalitis in a Greek pediatric hospital.
An 11-year-old Greek girl presented with clinical manifestations of acute psychosis. The differential diagnosis included viral encephalitis. The presence of a tumor usually an ovarian teratoma, a common clinical finding in many patients, was excluded. Early diagnosis and prompt immunotherapy resulted in full recovery up to one year after the initial diagnosis.
Acute psychosis is a rare psychiatric presentation in children, diagnosed only after possible organic syndromes that mimic acute psychosis are excluded, including anti-N-methyl-D-aspartate receptor receptor encephalitis. Pediatricians, neurologists and psychiatrists should consider this rare clinical syndrome, in order to make an early diagnosis and instigate appropriate treatment to maximize neurological recovery.
KeywordsNMDAR Encephalitis Psychosis Children
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis belongs to the autoimmune and paraneoplastic encephalitides . Initial reports of a syndrome characterized by psychiatric manifestations, memory loss, decreased consciousness, and hypoventilation in four young women with ovarian teratomas were published in 2005 . In 2007, auto-antibodies against the NMDAR were detected in these women and eight others with similar symptoms, seven of whom also had ovarian teratomas . Most patients exhibit psychosis, memory loss, seizures, and language disintegration, and may develop unresponsiveness with catatonic features or periods characterized by abnormal movements, including autonomic and breathing instability . Anti-NMDAR encephalitis mainly affects children and young adults and may be associated with malignancy. The presence of a tumor (usually an ovarian teratoma) is dependent on age, gender, and ethnicity, and is associated with a better prognosis after tumor resection and immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange) than in patients who do not have tumors. More than 75% of all patients recover in association with declining antibody titers but relapses are frequent and a close follow-up is necessary, at least for two years, after initial diagnosis .
In this report, we present a case of anti-NMDAR encephalitis that was diagnosed in an 11-year-old Greek girl who presented with subacute encephalopathy and psychiatric manifestations without evidence of malignancy. To the best of our knowledge, this is the first pediatric patient diagnosed with anti-NMDAR encephalitis in Greece.
A previously healthy 11-year-old girl with alternating confusion and agitation was admitted to the emergency department. She had a three day history of headaches, nausea, and sleepiness, 12 days prior to presentation at the hospital. Behavioral changes included low school performance, reduced food intake, troubled sleep, excessive and unintelligible speech referring mainly to her clothes, and panic possibly due to visual hallucinations, which intensified the day before admission. One week earlier, cranial magnetic resonance imaging (MRI) at another hospital was normal and she was diagnosed with an acute psychotic episode and prescribed olanzapine.
Patient’s characteristics and clinical manifestations, diagnostic findings and treatment
Patient’s characteristics and clinical manifestations
yes (urinary incontinence)
EEG-disorganized activity, focal or diffuse (non specific)
CSF protein concentration >45mg/dl
Substantial improvement/Full recovery
Extensive investigations for metabolic, infectious, toxic, autoimmune, central nervous system and psychiatric disorders were performed. An electroencephalogram (EEG) demonstrated right-side slowing without epileptiform discharges. Cranial MRI was normal. Her cerebrospinal fluid (CSF) examination was normal including polymerase chain reaction (PCR) for herpes simplex viruses (HSV-1,2) and negative serology for viruses (adenovirus, enterovirus, cytomegalovirus, measles and rubella), toxoplasma, and mycoplasma, but oligoclonal bands were demonstrated. Toxicology tests on blood and urine were negative. No evidence was found for possible metabolic causes, including Wilson’s disease and porphyria. Thyroid function was normal. Negative anti-nuclear antibodies, antiphospholipid antibody, normal titer of anti-deoxyribonucleic acid (DNA) antibody to native DNA and absence of antibody to Sm nuclear antigen excluded systemic lupus erythematosus. Serum immunoglobulin M (IgM) for human herpes virus 1, 2, 6, Epstein-Barr virus, cytomegalovirus, enterovirus, adenovirus, measles, mumps, rubella, chickenpox, parvovirus B19, borrelia, mycoplasma and toxoplasma was negative. Anti-NMDAR antibodies were revealed on immunohistochemistry in her serum and CSF. The association of anti-NMDAR antibodies with ovarian teratoma and other abdominal and thoracic tumors prompted pelvic ultrasonography, abdominal MRI and thoracic X-ray computed tomography (CT), all of which were normal. Testing for related tumor markers (alpha-fetal protein [α-FP], and human chorionic gonadotropin [β-hCG]) was negative.
Initial intervention was mostly symptomatic treatment of acute psychosis including diazepam (5–7.5mg/day IV), fluoxetine (10mg/day orally), risperidone (0.5mg orally 3 times per day) and biperiden (2mg orally 1 to 2 times per day). During severe episodes of agitation, she received midazolam (0.1mg/kg/dose IV).
Anti-NMDAR encephalitis was diagnosed 16 days after admission, and intravenous immunoglobulin (0.4g/kg every 24 hours for five days) and pulses of methylprednisolone (30mg/kg for five doses) were administered followed by oral prednisolone with progressive tapering of the dose. She also received three pulses of cyclophosphamide (750mg/m2), the first pulse 32 days after admission, and then at monthly intervals.
Symptoms improved following immunotherapy with steroids and intravenous immunoglobulin, and the frequency and duration of episodes of agitation and dystonia declined. The need for sedation medication (midazolam intravenous) was substantially reduced and discontinued after the last episode of agitation, on day 33. Fluoxetine was discontinued after the diagnosis of anti-NMDAR encephalitis; risperidone and diazepam were gradually withdrawn four weeks later. Communication and mobility improved 15 days after the administration of the first pulse of cyclophosphamide, and she was discharged on day 71 with mild dystonic gait and significant psychiatric manifestations; her verbal communication was poor, she had recent memory deficits, but she was able to read and make simple calculations. She demonstrated progressive improvement of cognitive and motor neurological functions over the next six months. She recovered fully and returned to school without apparent cognitive or behavioral problems after one year. Repeat testing for anti-NMDAR antibodies in her blood, five months after diagnosis, was negative and the EEG results were normal.
This clinical case presentation with symptoms resembling acute psychosis is consistent with the diagnosis of anti-NMDAR encephalitis, an autoimmune disorder described recently in young women with ovarian teratoma [3, 4]. The autoimmune pathogenesis  is mediated by antibodies, detected in serum and CSF, that mainly target the NR1 subunit of the NMDA receptor on the cell surface of neurons [3, 6].
It has been demonstrated that this disorder is more frequent in children than previously thought, and that clinical manifestations in pediatric patients are similar to those of adults . Prodromal symptoms such as low fever, headache, common cold-like symptoms, and gastroenteritis are found in most cases. The most frequent clinical presentation resembles acute psychosis  (anxiety, agitation, paranoia, visual and auditory hallucinations), but recognizing such symptoms in young children may be difficult. Dystonia and dyskinesias, abnormal movements of the face, tongue, limbs, trunk, and abdomen are common. Seizures can be noted although not demonstrated by EEG and there must be caution about any excessive use of antiepileptic drugs in these patients. Autonomic manifestations such as urinary incontinence and sleep dysfunction are common. However, more severe autonomic dysregulation such as central hypoventilation, dysrhythmia, tachycardia, and hyperthermia is rarely seen in children.
In children the frequency of teratoma  is low compared to that in adults. However, some tumors are detected many months after the initial encephalitic episode. Since some investigations have age-related limitations, all patients should undergo ultrasound and MRI of the abdomen and pelvis at initial diagnosis, as well as periodically for at least two years after the first episode.
Treatment includes surgical removal of ovarian teratoma or other tumors and prompt and aggressive immunotherapy [2, 8]. Some children appear to respond rapidly to intravenous immunoglobulin and methylprednisolone but may exhibit slow improvement independent of the treatment used. Other therapeutic options include cyclophosphamide, anti-CD20 monoclonal antibodies (rituximab), and plasma exchange, mainly in more severe/persistent cases. Studies published to date indicate a favorable prognosis for most young patients (75% respond to initial treatment, 29% recover fully, 45% improve significantly, and 26% reveal minor improvement) . The outcome improves following removal of a teratoma, if present, in combination with immunotherapy [9, 10]. Relapses have been noted in approximately 25% of young patients and seem to occur while tapering immunotherapy, as well as in cases without teratoma in those with high titers of anti-NMDAR antibodies in the CSF. Follow-up evaluation  should include neurologic and psychiatric examinations, ultrasound and MRI of the pelvis and abdomen, and measurements of the levels of anti-NMDAR antibodies’ titers in serum and CSF.
The diagnosis of ‘acute psychosis’ in children is rare and can be made only after possible organic causes are excluded. The differential diagnosis is broad, with viral encephalitis being the most likely alternative cause in these circumstances. Anti-NMDAR encephalitis is a new autoimmune disorder that commonly presents with psychiatric manifestations. Pediatricians, neurologists and psychiatrists should be aware of this disease’s clinical spectrum to identify and properly treat these patients.
Once specific anti-NMDAR antibodies are detected, it is crucial to start correct treatment, including tumor removal and intense immunotherapy, immediately. This disease has a good prognosis in the majority of cases if diagnosed early and treated properly.
Written informed consent was obtained from the patient’s parents for publication of this manuscript and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
herpes simplex virus
Magnetic resonance imaging
NMDA receptor 1
polymerase chain reaction
β-human horionic gonadotropin.
The authors thank Professor M. Dalakas, Head of the ‘Neuroimmunology unit’ of the Medical School of the National & Kapodistrian University of Athens (NKUA) as well as H. Alexopoulos, post-doctoral research associate in the same department who have standardized the laboratory protocols for anti-NMDAR antibodies identification in serum and CSF, in Greece.
- Kayser MS, Kohler CG, Dalmau J: Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry. 2010, 167: 1039-1050. 10.1176/appi.ajp.2010.09101547.View ArticlePubMed
- Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R: Clinical xperience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011, 10: 63-74. 10.1016/S1474-4422(10)70253-2.PubMed CentralView ArticlePubMed
- Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007, 61: 25-36. 10.1002/ana.21050.PubMed CentralView ArticlePubMed
- Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J: Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005, 58: 594-604. 10.1002/ana.20614.PubMed CentralView ArticlePubMed
- Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J: Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol. 2011, 231: 86-91. 10.1016/j.jneuroim.2010.09.012.View ArticlePubMed
- Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR: Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008, 7: 1091-1098. 10.1016/S1474-4422(08)70224-2.PubMed CentralView ArticlePubMed
- Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009, 66: 11-18. 10.1002/ana.21756.PubMed CentralView ArticlePubMed
- Graus F, Dalmau J: Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol. 2007, 20: 732-737.PubMed
- Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, Suzuki K, Lynch DR, Suzuki N, Hata T, Dalmau J: Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology. 2008, 70: 504-511. 10.1212/01.wnl.0000278388.90370.c3.PubMed CentralView ArticlePubMed
- Ishiura H, Matsuda S, Higashihara M, Hasegawa M, Hida A, Hanajima R, Yamamoto T, Shimizu J, Dalmau J, Tsuji S: Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology. 2008, 71: 1921-1923. 10.1212/01.wnl.0000336648.43562.59.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.